A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations

被引：0
|
作者：
Tamiya, Akihiro
Tamiya, Motohiro
Nakatani, Akeshi
Shiroyama, Talcayuki
Kitai, Kanako
Tsuji, Taisuke
Morishita, Naoko
Omachi, Naold
Asami, Kazuhiro
Okamoto, Norio
Suzuki, Hidekazu
Okishio, Kyoichi
Kawaguchi, Tomoya
Hiroshima, Tomonort
Atagi, Shinji
机构：
[1] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Osaka, Japan
[2] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Habikino, Japan
[3] Kinki Chuo Chest Med Ctr, Osaka, Japan
[4] Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Osaka, Japan
[5] Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan
[6] Natl Hosp Org, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[7] Osaka Prefectural Hosp Org, Osaka Prefectural Med Ctr Resp & Allerg Dis, Dept Thorac Malignancy, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e19095
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19095
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
    Tamiya, Akihiro
    Tamiya, Motohiro
    Shiroyama, Takayuki
    Saijo, Nobuhiko
    Nakatani, Takeshi
    Minomo, Shojiro
    Tsuji, Taisuke
    Takeuchi, Naoko
    Omachi, Naoki
    Kurata, Kanako
    Suzuki, Hidekazu.
    Okamoto, Norio
    Okishio, Kyoichi
    Hirashima, Tomonori
    Atagi, Shinji
    [J]. MEDICAL ONCOLOGY, 2015, 32 (03) : 1 - 7
  • [2] Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
    Akihiro Tamiya
    Motohiro Tamiya
    Takayuki Shiroyama
    Nobuhiko Saijo
    Takeshi Nakatani
    Shojiro Minomo
    Taisuke Tsuji
    Naoko Takeuchi
    Naoki Omachi
    Kanako Kurata
    Hidekazu. Suzuki
    Norio Okamoto
    Kyoichi Okishio
    Tomonori Hirashima
    Shinji Atagi
    [J]. Medical Oncology, 2015, 32
  • [3] Final analysis of phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
    Tanaka, A.
    Tamiya, A.
    Tamiya, M.
    Morita, S.
    Shiroyama, T.
    Saijo, N.
    Minomo, S.
    Tsuji, T.
    Takeuchi, N.
    Omachi, N.
    Morishita, N.
    Suzuki, H.
    Okamoto, N.
    Okishio, K.
    Hirashima, T.
    Atagi, S.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 : 136 - 136
  • [4] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    H Asahina
    K Yamazaki
    I Kinoshita
    N Sukoh
    M Harada
    H Yokouchi
    T Ishida
    S Ogura
    T Kojima
    Y Okamoto
    Y Fujita
    H Dosaka–Akita
    H Isobe
    M Nishimura
    [J]. British Journal of Cancer, 2006, 95 : 998 - 1004
  • [5] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Asahina, H.
    Yamazaki, K.
    Kinoshita, I.
    Sukoh, N.
    Harada, M.
    Yokouchi, H.
    Ishida, T.
    Ogura, S.
    Kojima, T.
    Okamoto, Y.
    Fujita, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004
  • [6] First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
    Inoue, Akira
    Kobayashi, Kunihiko
    Usui, Kazuhiro
    Maemondo, Makoto
    Okinaga, Shoji
    Mikami, Iwao
    Ando, Masahiro
    Yamazaki, Koichi
    Saijo, Yasuo
    Gemma, Akihiko
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Ikebuchi, Kenji
    Nukiwa, Toshihiro
    Morita, Satoshi
    Hagiwara, Koichi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1394 - 1400
  • [7] First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations NEJ 003 Study
    Maemondo, Makoto
    Minegishi, Yuji
    Inoue, Akira
    Kobayashi, Kunihiko
    Harada, Masao
    Okinaga, Shoji
    Morikawa, Naoto
    Oizumi, Satoshi
    Tanaka, Tomoaki
    Isobe, Hiroshi
    Kudoh, Shoji
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    Gemma, Akihiko
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1417 - 1422
  • [8] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [9] Phase II study of gefitinib as first-line chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations and poor prognostic characteristics.
    Murakami, Shuji
    Manabe, Saki
    Kondo, Tetsuro
    Saito, Haruhiro
    Yamada, Kouzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] A Phase II Study of First-Line Chemotherapy with Weekly Carboplatin Plus Gemcitabine in Advanced Non-Small Cell Lung Cancer
    Mori, Kiyoshi
    Kamiyama, Yukari
    Kasai, Hisashi
    Kodama, Tetsuro
    [J]. CHEMOTHERAPY, 2012, 58 (01) : 78 - 83
12345